This article is more than 5 years old. Information may no longer be current.
IBS: Still Treating Subsets for Lack of Known Mechanisms
Click Here to Manage Email Alerts
The amount of data presented at Digestive Disease Week 2015 regarding irritable bowel syndrome attests to the need and desire for more knowledge of this multi-faceted disease.
In this month’s cover story, three leading experts in IBS discuss the latest developments in diarrhea-predominant IBS (IBS-D), including new biomarkers and new treatments based on mechanisms of action.
“These recent events are exciting because they open a door to a number of new options for clinicians who are taking care of patients with IBS and diarrhea,” William D. Chey, MD, told Healio Gastroenterology.
While forcing physicians to consider this as a disease and not a syndrome, these new perspectives on IBS-D, but not in constipation-predominant IBS and other forms of the disease, continue the quest for more overarching treatments.
“What we’re doing is developing drugs that are likely to improve symptoms in a subset of IBS sufferers, but as long as IBS remains a purely symptom-based condition, there really isn’t ever going to be a silver bullet that makes all IBS sufferers better,” Chey said.
See our continued Meeting News Coverage from DDW and our In the Journals section for more news on IBS and other gastrointestinal hot topics.
Your interactions with our content online will continue to shape our print content. As long as our readers keep talking, we’ll keep listening with every headline we write.
The Editors
Healio Gastroenterology
gastroenterology@slackinc.com